GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » Cyclically Adjusted PB Ratio

Novelion Therapeutics (STU:QLTA) Cyclically Adjusted PB Ratio : (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Novelion Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novelion Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Novelion Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics Cyclically Adjusted PB Ratio Chart

Novelion Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novelion Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Novelion Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Novelion Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novelion Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novelion Therapeutics's Cyclically Adjusted PB Ratio falls into.



Novelion Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novelion Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2019 is calculated as:

For example, Novelion Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2019 was:

Adj_Book=Book Value per Share/CPI of Mar. 2019 (Change)*Current CPI (Mar. 2019)
=-5.681/106.9792*106.9792
=-5.681

Current CPI (Mar. 2019) = 106.9792.

Novelion Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
200906 19.757 90.940 23.242
200909 19.681 90.624 23.233
200912 25.791 90.703 30.419
201003 28.015 91.335 32.813
201006 31.172 91.809 36.323
201009 -6.534 92.362 -7.568
201012 27.558 92.836 31.756
201103 25.452 94.338 28.863
201106 24.374 94.654 27.548
201109 24.897 95.286 27.952
201112 25.552 94.970 28.783
201203 24.689 96.155 27.468
201206 25.013 96.076 27.852
201209 30.311 96.392 33.640
201212 28.678 95.760 32.038
201303 28.427 97.103 31.318
201306 12.581 97.182 13.849
201309 11.884 97.419 13.050
201312 11.274 96.945 12.441
201403 10.748 98.604 11.661
201406 10.349 99.473 11.130
201409 10.631 99.394 11.442
201412 12.396 98.367 13.481
201503 13.628 99.789 14.610
201506 12.455 100.500 13.258
201509 12.229 100.421 13.028
201512 12.280 99.947 13.144
201603 10.152 101.054 10.747
201606 6.744 102.002 7.073
201609 6.298 101.765 6.621
201612 6.947 101.449 7.326
201703 5.396 102.634 5.624
201706 4.183 103.029 4.343
201709 1.733 103.345 1.794
201712 0.681 103.345 0.705
201803 -0.571 105.004 -0.582
201806 -2.077 105.557 -2.105
201809 -3.200 105.636 -3.241
201812 -4.215 105.399 -4.278
201903 -5.681 106.979 -5.681

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novelion Therapeutics  (STU:QLTA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novelion Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novelion Therapeutics (STU:QLTA) Business Description

Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.